Focused On-demand Library for Peroxisomal biogenesis factor 19

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

33 kDa housekeeping protein; Peroxin-19; Peroxisomal farnesylated protein

Alternative UPACC:

P40855; D3DVE7; E9PPB4; G3V3G9; Q5QNY4; Q8NI97


Peroxisomal biogenesis factor 19, also known as Peroxin-19, plays a crucial role in early peroxisomal biogenesis. It functions as a cytosolic chaperone and an import receptor for peroxisomal membrane proteins (PMPs), facilitating their stabilization and targeting to the peroxisome membrane. This protein's interaction with PEX3 is vital for the import process, and it also plays a role in excluding CDKN2A from the nucleus, thereby regulating TP53 degradation.

Therapeutic significance:

Peroxisomal biogenesis factor 19 is implicated in peroxisome biogenesis disorders, including Zellweger syndrome and neonatal adrenoleukodystrophy. These conditions are characterized by severe neurologic dysfunction, liver dysfunction, and early mortality. Understanding the role of Peroxisomal biogenesis factor 19 could open doors to potential therapeutic strategies for these life-threatening disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.